Evidence-based·Updated November 19, 2026·How we grade evidence

Pentadecanoic acid (C15:0)

Fatty-acidOdd-chain saturated fatty acid

C15:0 capsules raise blood C15:0 levels. Two small 12-week trials found at most small changes in liver enzymes or LDL cholesterol, and the links with less diabetes and lower blood pressure come from observational studies that cannot show cause and effect.

Taking Pentadecanoic acid (C15:0) with other supplements or medications?Check your whole list for interactions. Free, no account.

Quick decision guide

May help most

Adults curious about the research who understand the evidence is early; there is no group for whom a benefit has been shown

Common dosing range

200 mg per day was the dose in the 12-week trial in young adults (two 100 mg capsules each morning)

When to expect effects

Blood levels rose within 12 weeks; no health effect has been confirmed

Watch out for

Only short, small trials exist, and much of the research is funded by the company that sells it; safety beyond 12 weeks, in pregnancy and in children is unknown

What is it

Pentadecanoic acid, usually written C15:0, is a saturated fat with 15 carbon atoms. It is called an odd-chain fatty acid because most fats in food have an even number of carbons. It occurs in small amounts in dairy fat and in some fish and plants, and blood levels of C15:0 are used in research as a marker of how much dairy fat people eat. It is now sold as a capsule supplement. Much of the research and promotion behind it comes from the company that sells it: in a 2020 laboratory paper that proposed C15:0 as a potential essential fatty acid, the lead scientist declared that she co-founded and works for Epitracker and Seraphina Therapeutics, which financed studies in that paper and hold licensing rights from the U.S. Navy to sell odd-chain fatty acids as health products. Most of the human evidence is observational (people with higher blood levels compared with people with lower levels); two small 12-week trials with added C15:0 have been published.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You want to try it knowing that the placebo-controlled capsule trial in young adults (30 people, 12 weeks) showed a rise in blood levels, not a proven health benefit
You prefer to discuss it with your doctor first and check liver enzymes and cholesterol before and after, as the trials did

Probably skip if…

You are looking for a proven way to prevent diabetes, heart disease or aging
You are pregnant, breastfeeding, or buying for a child or teenager, since none of these groups has been studied
You want to use it in place of treatment for fatty liver, high cholesterol or high blood pressure

Evidence at a glance

blood C15:0 levels

Limited Evidence
Effect
Blood C15:0 1.88 μg/mL higher than placebo after 12 weeks
Best fit
Young adults with overweight or obesity (the only group studied with capsules)
Time
12 weeks

liver enzymes and liver fat

Limited Evidence
Effect
GGT 11 U/L lower than placebo; no clear extra effect on liver fat beyond diet
Best fit
Adults with overweight or fatty liver, as studied
Time
12 weeks

LDL cholesterol

Limited Evidence
Effect
Extra LDL lowering beyond diet in one trial; size not stated in the abstract
Best fit
Women with fatty liver who were also losing weight on a structured diet
Time
12 weeks

type 2 diabetes risk (observational only)

Mixed Evidence
Effect
About 20 to 32 percent lower diabetes rates with higher blood levels (association)
Best fit
Not established
Time
Not applicable (observational)

blood pressure and heart disease (observational only)

Mixed Evidence
Effect
About 1 to 1.5 mm Hg lower blood pressure per standard deviation (association); no link with heart disease
Best fit
Not established
Time
Not applicable (observational)

inflammation, anemia and aging (cell and animal studies only)

Mixed Evidence
Effect
Not measured in humans
Best fit
Not established
Time
Unknown

Evidence for 6 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

blood C15:0 levels

Biomarker support
Limited Evidence

In a 12-week double-blind trial in 30 adults aged 18 to 25 with overweight or obesity (average age 20, average BMI 33.4), 20 took 200 mg of C15:0 a day and 10 took placebo. Blood C15:0 rose by 1.88 μg/mL more than with placebo. Half of the people taking C15:0 reached a level above 5 μg/mL, a threshold proposed in earlier research, including the company's own. The trial was partially supported by the NIH and also by Seraphina Therapeutics, including the C15:0 capsules and matching placebo; the authors declared no conflict with the company.

Effect size
Blood C15:0 1.88 μg/mL higher than placebo after 12 weeks
Time to effect
12 weeks
Best fit
Young adults with overweight or obesity (the only group studied with capsules)
Less likely
Anyone hoping a higher blood level alone means better health; that has not been shown

Bottom line: The capsules do raise blood C15:0; whether that helps health is unproven.

liver enzymes and liver fat

Biomarker support
Limited Evidence

In the 12-week trial of 30 young adults, C15:0 lowered the liver enzyme GGT by 11 U/L more than placebo, but did not change ALT, AST or the other measured outcomes compared with placebo. Larger drops in ALT and AST were seen only in an exploratory comparison of people who reached higher blood levels. In the TANGO trial, 88 Chinese women with fatty liver followed an Asian-adapted Mediterranean-style diet with or without added C15:0, or their usual diet, for 12 weeks. Liver fat fell by 33 percent with diet plus C15:0, 30 percent with diet alone and 10 percent with usual diet; the abstract reports an added effect of C15:0 for LDL cholesterol and one gut bacterium, while the drop in liver fat was similar with diet alone and went along with weight loss. TANGO was funded by Singapore's Agency for Science, Technology and Research (A*STAR), its trial registry lists the food company Wilmar International as a collaborator, and its authors declared no conflicts of interest.

Effect size
GGT 11 U/L lower than placebo; no clear extra effect on liver fat beyond diet
Time to effect
12 weeks
Best fit
Adults with overweight or fatty liver, as studied
Less likely
People expecting C15:0 to replace weight loss for fatty liver

Bottom line: A small change in one liver enzyme; diet did the heavy lifting for liver fat.

Evidence is mixed

ALT and AST did not change compared with placebo in the capsule trial, and in TANGO the liver fat drop was similar with or without C15:0.

LDL cholesterol

Biomarker support
Limited Evidence

In the TANGO trial (88 Chinese women with fatty liver, 12 weeks), adding C15:0 to an Asian-adapted Mediterranean-style diet lowered LDL cholesterol further than the diet alone. The abstract does not give the size of the extra drop. In the separate 12-week capsule trial in 30 young adults, cholesterol did not change compared with placebo.

Effect size
Extra LDL lowering beyond diet in one trial; size not stated in the abstract
Time to effect
12 weeks
Best fit
Women with fatty liver who were also losing weight on a structured diet
Less likely
People with high cholesterol who need proven treatment

Bottom line: One trial suggests a small extra LDL drop; it has not been confirmed.

Evidence is mixed

The capsule trial in young adults found no cholesterol change compared with placebo.

type 2 diabetes risk (observational only)

Biomarker support
Mixed Evidence

A pooled analysis of 16 cohort studies (63,682 adults followed for about 9 years) found that people with blood C15:0 at the high end of their cohort's range had a 20 percent lower rate of type 2 diabetes than those at the low end (hazard ratio 0.80). A 2026 review of 27 articles on prospective cohort studies found a similar link (summary relative risk 0.68 for higher C15:0 in blood phospholipids and red blood cells, moderate certainty). These studies measured blood levels that mostly reflect dairy fat intake, not supplement use. They cannot show that C15:0 prevents diabetes, and no trial has tested whether a C15:0 supplement lowers diabetes risk.

Effect size
About 20 to 32 percent lower diabetes rates with higher blood levels (association)
Time to effect
Not applicable (observational)
Best fit
Not established
Less likely
Anyone expecting a supplement to reproduce a link seen with dairy-rich diets

Bottom line: An interesting association, not proof that a C15:0 pill prevents diabetes.

blood pressure and heart disease (observational only)

Biomarker support
Mixed Evidence

In 3,196 adults from the US CARDIA study (average age 45), each standard-deviation increase in blood C15:0 went with 1.47 mm Hg lower systolic and 1.13 mm Hg lower diastolic blood pressure and a 14 percent lower rate of new high blood pressure over about 10 years; these links were repeated in 3,889 White adults from the ARIC study (average age 54). Blood C15:0 was not linked to new heart disease in either group or to heart function. A genetic analysis designed to test cause and effect found no evidence that C15:0 lowers blood pressure, and the authors concluded the evidence is not consistent with a causal heart benefit. The authors declared no commercial conflicts and reported funding from the US National Heart, Lung, and Blood Institute.

Effect size
About 1 to 1.5 mm Hg lower blood pressure per standard deviation (association); no link with heart disease
Time to effect
Not applicable (observational)
Best fit
Not established
Less likely
People seeking heart protection

Bottom line: Small blood pressure links, no heart disease link, and no sign of cause and effect.

inflammation, anemia and aging (cell and animal studies only)

Mechanism only
Mixed Evidence

In cell and animal studies, C15:0 lowered markers of inflammation, anemia, high blood fats and scarring, and the authors proposed it as a potential essential fatty acid. The paper declares that studies in it were financed by Epitracker and Seraphina Therapeutics, companies co-founded by the lead author that hold exclusive licensing rights to sell odd-chain fatty acids as health products. A 2024 review by the same scientist, who declares that she is employed by both companies, proposed a "Cellular Stability Hypothesis" and a C15:0 deficiency syndrome. These effects and ideas have not been shown in people; the claims about aging and longevity rest on laboratory work.

Effect size
Not measured in humans
Time to effect
Unknown
Best fit
Not established
Less likely
Anyone treating anemia, inflammation or aging-related disease

Bottom line: Laboratory findings from company-funded work, not human benefits.

How it works

In cell and animal studies financed in part by the company that sells C15:0, the fatty acid lowered markers of inflammation, anemia, high blood fats and scarring, and the authors proposed that it works by binding to key metabolic regulators and supporting mitochondria (the energy-making parts of cells). In a 2024 review, an employee of the same company proposed a "cellular stability hypothesis": that C15:0 strengthens cell membranes and that low blood levels amount to a nutritional deficiency syndrome. These are hypotheses from the company's own scientists and have not been tested as such in people. In large population studies, people with higher blood C15:0 had lower rates of type 2 diabetes and slightly lower blood pressure. Because blood C15:0 mostly reflects dairy fat intake, these links may reflect diet and lifestyle rather than C15:0 itself. A 2026 study that used genetic data to test cause and effect found no evidence that C15:0 itself lowers blood pressure.

How to take it

1. Typical dose
Studied dose: 200 mg per day of C15:0 as a free fatty acid (two 100 mg capsules each morning) in a 12-week trial in young adults with overweight or obesity. There is no established dose.
2. Higher studied dose
No higher daily dose has been tested for weeks at a time in a published trial with a stated dose (the TANGO trial's C15:0 amount is not given in its abstract or registry). A single 2.5 g dose, given once in a test meal, was used in a 2013 study of a fat-absorption blood test in 15 healthy adults and 6 people with cystic fibrosis.
3. Timing
In the trial, capsules were taken in the morning
4. With food
Not specified in the trial
5. Split dosing
Not studied
6. How long to try
Trials lasted 12 weeks; longer use has not been studied

What to track

Liver enzymes (ALT, AST, GGT) and cholesterol if your doctor checks them, since these were the trial measures
Any digestive or other new symptoms

Bottom line: A dose has been tested for 12 weeks; a health benefit has not been shown.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

No significant adverse events were reported in the 12-week trial of 200 mg per day in 30 young adults

Serious risks

Who should avoid it

  • Pregnant or breastfeeding women, since there are no human studies; in pregnant mice, a diet with 1 percent C15:0 caused mild glucose intolerance
  • Children and teenagers, who have not been studied (the capsule trial enrolled ages 18 to 25)

Pregnancy & breastfeeding

C15:0 supplements have not been studied in pregnancy or breastfeeding. In one mouse study, a diet containing 1 percent C15:0 during pregnancy caused mild insulin resistance in the mothers, though it did not affect embryo development. Talk with your doctor before using it while pregnant or breastfeeding.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Milligrams of C15:0 per capsule (the trial used two 100 mg capsules a day)
Form stated (the trial used pure C15:0 as a free fatty acid)
Independent third-party testing for content and purity

Be skeptical of…

"The first new essential fatty acid" (a proposal by company-linked scientists, not an established nutrient status)
"Fixes C15:0 deficiency syndrome" or "cellular fragility syndrome" (a company hypothesis, not a recognized diagnosis)
"Proven longevity" or "anti-aging" (based on cell and animal studies)
"Prevents diabetes" or "protects your heart" (observational links only, and a genetic study found no heart benefit)

Frequently asked questions

Is C15:0 really an essential fatty acid?⌄

That idea was proposed by scientists linked to the companies that sells C15:0, based mainly on cell and animal studies. Essential means the body cannot make it and needs it from food to avoid a deficiency disease. No human trial has shown a deficiency disease that C15:0 supplements prevent or treat.

Who funded the research?⌄

The 2020 laboratory and animal paper that proposed C15:0 as a potential essential fatty acid declares that studies in it were financed by Epitracker and Seraphina Therapeutics, companies co-founded by the lead author. The 12-week capsule trial in young adults was partially supported by the NIH and by Seraphina Therapeutics, which supplied the capsules and placebo. The TANGO diet trial was funded by a Singapore government research agency (its registry lists the food company Wilmar International as a collaborator), and the 2026 CARDIA and ARIC blood pressure study reported NIH funding; the authors of both declared no conflicts of interest.

Is it better to eat dairy fat or take a C15:0 capsule?⌄

Neither has been proven to prevent disease. The links between higher blood C15:0 and less diabetes come from people whose levels mostly reflect dairy fat in their diet, so those findings say nothing direct about capsules. A 2026 genetic study found no evidence that C15:0 itself lowers blood pressure.

Can I take C15:0 with my medicines or other supplements?⌄

No interaction studies have been published for C15:0 supplements. Because the evidence is so limited, ask your doctor or pharmacist to look at your own list before you start, especially if you take medicines for cholesterol, diabetes or liver disease.

Is C15:0 safe?⌄

In a 12-week trial of 200 mg a day in 30 young adults, no significant side effects occurred. Nothing is known about longer use, use in older adults with health problems, pregnancy or children.

References by claim

blood C15:0 levels

Robinson et al., 2024 · PMC (2024) link

liver enzymes and liver fat

Chooi et al., 2024 · PubMed (2024) link

type 2 diabetes risk (observational only)

Imamura et al., 2018 · PMC (2018) link

Schaefer et al., 2026 · PMC (2026) link

blood pressure and heart disease (observational only)

Steffen et al., 2026 · PMC (2026) link

inflammation, anemia and aging (cell and animal studies only)

Venn-Watson et al., 2020 · PMC (2020) link

Venn-Watson et al., 2024 · PMC (2024) link

Safety

Wang et al., 2024 · PubMed (2024) link

Track Pentadecanoic acid (C15:0) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments. Talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.